跳至主要内容
临床试验/NCT00038896
NCT00038896已完成3 期

A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder

Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 343 人开始时间: 2001年4月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
343

研究概览

简要总结

The primary objective of this study is to determine the efficacy, safety, and tolerability of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks in the treatment of adult outpatients with panic disorder (PD) in a placebo-controlled phase III study.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • A male or female outpatient
  • Be at least 18 years of age and legal age of consent
  • Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months before study day 1

排除标准

  • Treatment with venlafaxine (IR or ER) within 6 months of study day 1
  • Known hypersensitivity to venlafaxine (IR or ER) or related compounds
  • History or presence of any clinically important hepatic, renal, or other medical disease that might compromise the study or be detrimental to the patient (eg, clinically important cardiac arrhythmia, unstable diabetes, carcinoma [except basal cell epithelioma], uncontrolled hypertension)

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

相似试验

Study Evaluating Venlafaxine ER in Adults With Panic... | 临床试验